After Johnson and Johnson, Merck and AstraZeneca, another multinational pharmaceutical company launches its innovation collaboration center in China

"
Pharmaceutical Network Corporate News: Following Johnson, Johnson, Merck and AstraZeneca, Bollinger Ingerheim also announced the launch of its Innovation Cooperation Center in ChinaRecently, Gao Qifei, President and CEO of Global Pharmaceutical Giant Brigingham Greater China, announced in Shanghai the official launch of The Boehringer Ingerheim China External Innovation Cooperation CenterOne of the highlights of TheLaunch of China's External Innovation Cooperation Center is the adoption of the first "three-in-one" business model of multinational pharmaceutical companies, namely, academic cooperation (cross-border research), business development and licensing, venture capital investment in onethe objectives of this project are several: first, to provide early research support in collaboration with academic research institutions in the field of drug research and development in the main therapeutic areas of Bollinger Ingham and in disease areas where there are a large number of unmet medical needs;this innovative business model facilitates one-stop innovative collaborative solutions for innovators in the biopharmaceutical industry in China and Asia, with a full process of helping them realize innovative ideas, from early research and innovation collaboration stooping to strategic investmentat present, Bollinger Ingerheim China External Innovation Cooperation Center has established strategic cooperative relations with Tsinghua University, Peking University and other institutions on comprehensive cooperation and early scientific research, as well as various cooperative relationships with various research institutes of the Chinese Academy of Sciences and a number of scientific research institutions, and a number of research results have been published in the journalChina has become a global innovation center, and Bollinger Ingham has seized the opportunity to continue to make its caseAfter continuous layout, China has become the company's first global possession of human medicine, animal health, biopharmaceuticals and health innovation division of the four business units of the regional marketFor the full year of 2019 and in the first quarter of 2020, Bollinger Ingham China achieved double-digit growththis year also the 25th anniversary of Bollinger Ingham's entry into ChinaIt is reported that in the next five years, Bollinger Ingerheim will continue to increase investment in China, the current confirmed capital increase of up to 451 million euros over the next five years, mainly for the expansion of animal health and biopharmaceutical business production base and clinical research and development investmentIn addition to the launch of the China External Innovation Center, the company will also lay out innovations, including BI X, a digital innovation laboratory in Shanghai, announced in Marchit is also worth mentioning that Bollinger Ingerheim is also the first multinational pharmaceutical company to achieve early clinical global synchronization in China At the end of 2019, Bollinger Ingham announced that China will be fully integrated into its global early clinical development projects, and with the advancement of its China Key project, Bollinger Ingham China is expected to have 71 new products or new indications approved in China over the next 10 years from the perspective of the general environment, with the domestic generic drug consistency evaluation and the promotion of the volume procurement policy, foreign pharmaceutical enterprises are facing the impact of the original research and market challenges In this context, the major pharmaceutical companies on the one hand to speed up the introduction of new drugs, expand their product pipelinein in China, on the other hand, also hope that the rise of innovative drugs in China in the tide of "wind and waves", all kinds of innovation cooperation centers or external strategic alliances continue to emerge.